MLH1 Loss in Primary Prostate Cancer
JCO Precision Oncology · 2023
DOI: 10.1200/po.22.00611 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Sanaz Nourmohammadi Abadchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD. Hauptthemen laut MEDLINE: DNA Methylation, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Among mismatch repair-deficient (MMRd) prostate cancers, loss of MLH1 is relatively uncommon and few cases have been reported in detail. METHODS Here, we describe the molecular features of two cases of primary prostate cancer with MLH1 loss detected by immunohistochemistry, and in one case, confirmed via transcriptomic profiling. RESULTS Both cases were microsatellite stable on standard polymerase chain reaction (PCR)–based microsatellite instability (MSI) testing, but showed evidence of MSI on a newer PCR-based long mononucleotide repeat (LMR) assay and by next-generation sequencing. Germline testing was negative for Lynch syndrome–associated mutations in both cases. Targeted or whole-exome tumor sequencing using multiple commercial/academic platforms (Foundation, Tempus, JHU, and UW-OncoPlex) showed modestly elevated, though variable, tumor mutation burden estimates (2.3-10 mutations/Mb) consistent with MMRd, but without identifiable pathogenic single-nucleotide or indel mutations in MLH1. Copy-number analysis confirmed biallelic MLH1 loss in one case and monoallelic MLH1 loss in the second case, without evidence of MLH1 promoter hypermethylation in either. The second patient was treated with single-agent pembrolizumab and demonstrated a short-lived prostate-specific antigen response. CONCLUSION These cases highlight the challenges in identifying MLH1-deficient prostate cancers using standard MSI testing and commercial sequencing panels, and support the utility of immunohistochemical assays and LMR- or sequencing-based MSI testing for detection of MMRd prostate cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD.
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD.
- University of Minnesota Masonic Cancer Center, Minneapolis, MN.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
- The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD.
- Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD.
ORCID-Profile: Sanaz Nourmohammadi Abadchi, Laura A Sena, Emmanuel S Antonarakis, Colin C Pritchard, James R Eshleman, Eric Q Konnick, Stephen J Salipante, Eugene Shenderov, Tamara L Lotan
Förderung
- NCI NIH HHS
Zitieren
APA
Nourmohammadi Abadchi, S., Sena, L. A., Antonarakis, E. S., Pritchard, C. C., Eshleman, J. R., Konnick, E. Q., Salipante, S. J., Shenderov, E., & Lotan, T. L. (2023). MLH1 Loss in Primary Prostate Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.22.00611
Vancouver
Nourmohammadi Abadchi S, Sena LA, Antonarakis ES, Pritchard CC, Eshleman JR, Konnick EQ, et al. MLH1 Loss in Primary Prostate Cancer. JCO Precision Oncology. 2023. doi:10.1200/po.22.00611
BibTeX
@article{NourmohammadiAbadchi2023,
author = {Nourmohammadi Abadchi, Sanaz and Sena, Laura A and Antonarakis, Emmanuel S and Pritchard, Colin C and Eshleman, James R and Konnick, Eric Q and Salipante, Stephen J and Shenderov, Eugene and Lotan, Tamara L},
title = {MLH1 Loss in Primary Prostate Cancer},
journal = {JCO Precision Oncology},
year = {2023},
doi = {10.1200/po.22.00611}
}
EUVIMED